Cullinan Therapeutics Inc (NASDAQ: CGEM) on Friday, soared 14.55% from the previous trading day, before settling in for the closing price of $7.56. Within the past 52 weeks, CGEM’s price has moved between $5.68 and $17.50.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -45.66%. The company achieved an average annual earnings per share of -35.12%. With a float of $36.85 million, this company’s outstanding shares have now reached $59.07 million.
Considering the fact that the conglomerate employs 111 people, you should pay attention to its efficiency factor.
Cullinan Therapeutics Inc (CGEM) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cullinan Therapeutics Inc is 37.61%, while institutional ownership is 78.56%. The most recent insider transaction that took place on Oct 28 ’25, was worth 1,391,686. In this transaction 10% Owner of this company bought 165,667 shares at a rate of $8.40, taking the stock ownership to the 8,963,500 shares. Before that another transaction happened on Oct 16 ’25, when Company’s 10% Owner bought 150,000 for $8.86, making the entire transaction worth $1,328,250. This insider now owns 8,765,616 shares in total.
Cullinan Therapeutics Inc (CGEM) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.69 earnings per share (EPS) for the period topping the consensus outlook (set at -0.77) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.59% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Cullinan Therapeutics Inc (CGEM) is currently performing well based on its current performance indicators. A quick ratio of 9.83 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.52, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -3.58 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Compared to the last year’s volume of 0.56 million, its volume of 1.0 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 33.41%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 83.47%, which indicates a significant increase from 71.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.71 in the past 14 days, which was higher than the 0.44 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.09, while its 200-day Moving Average is $8.06. Nevertheless, the first resistance level for the watch stands at $9.08 in the near term. At $9.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.22. If the price goes on to break the first support level at $7.94, it is likely to go to the next support level at $7.22. Should the price break the second support level, the third support level stands at $6.80.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
Market capitalization of the company is 511.58 million based on 59,074K outstanding shares. Right now, sales total 0 K and income totals -167,380 K. The company made 0 K in profit during its latest quarter, and -70,060 K in sales during its previous quarter.
